VivoSeq
Other

Opioid Consumption

0

Pipeline Programs

4

Active Trials

0

Companies Involved

Opioid Consumption is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

5/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

20

clinical trials

Completed13 · 65%
Not yet recruiting2 · 10%
Unknown status2 · 10%
Recruiting1 · 5%
Withdrawn1 · 5%
Active, not recruiting1 · 5%

Trial Activity

20 trials

Intravenous Acetaminophen to Reduce Post-operative Opioid Consumption
Not yet recruiting··Phase 4·NCT06923540·140 enrolled
Gabapentin Regimens and Their Effects on Opioid Consumption
Completed··Phase 4·NCT03334903·77 enrolled
Scalp Nerve Block and Opioid Consumption in Brain Surgery
Completed··Phase 4·NCT02057367·100 enrolled
Duloxetine Role in Reducing Opioid Consumption After Thoracotomy
Completed··Phase 4·NCT03618225·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)